Blasco-Turrión, SaraCrespo-Leiro, María GenerosaDonoso Trenado, VíctorLi Chi Hion, PedroDíaz-Molina, BeatrizRoura, GerardPan Álvarez-Osorio, ManuelGómez-Bueno, ManuelOrtiz-Bautista, CarlosDíaz Fernández, José FranciscoGarrido-Bravo, Iris P.Moreno, RaúlSarnago-Cebada, FernandoSalterain-González, NahikariTorre Hernández, José María de laGarcía del Blanco, BrunoFarrero-Torres, MartaOrtas Nadal, RosarioMartín, Pedro L.De la Fuente, LuisSanz-Sánchez, JorgeMirabet, SoniaAlonso Fernández, VanesaGómez Hospital, Joan AntoniLópez-Granados, AmadorCouto-Mallón, DavidTrigo Espinosa, María delRangel Sousa, DiegoZatarain Nicolás, EduardoArzamendi Aizpurua, DabitLópez-Vilella, RaquelSan Román, José AlbertoAmat-Santos, Ignacio C.2024-11-222024-07-09Blasco-Turrión S, Crespo-Leiro MG, Donoso Trenado V, Chi Hion PL, Díaz Molina B, Roura G, Álvarez-Osorio MP, Gómez-Bueno M, Ortiz Bautista C, Diaz JF, Garrido Bravo IP, Moreno R, Sarnago-Cebada F, Salterain González N, de la Torre Hernandez JM, García Del Blanco B, Farrero M, Ortas Nadal R, Martin P, de La Fuente L, Sanz-Sánchez J, Mirabet Pérez S, Alonso Fernández V, Gómez Hospital JA, López Granados A, Couto-Mallon D, Del Trigo Espinosa M, Rangel Sousa D, Zatarain-Nicolás E, Arzamendi Aizpurua D, López Vilella R, San Román JA, Amat-Santos IJ. Structural heart transcatheter interventions in orthotopic cardiac transplant and left ventricular assist devices recipients: a nationwide study. Int J Cardiol. 2024 Oct 15;413:132340.0167-5273http://hdl.handle.net/2183/40254Observational study[Abstract] Background: The current incidence and outcomes of structural transcatheter procedures in heart transplant (HTx) recipients and left-ventricular assist devices (LVAD) carriers is unknown. Aims: To provide insights on structural transcatheter procedures performed across HTx and LVAD patients in Spain. Methods: Multicenter, ambispective, observational nationwide registry. Results: Until May/2023, 36 percutaneous structural interventions were performed (78% for HTx and 22% for LVAD) widely varying among centers (0%-1.4% and 0%-25%, respectively). Percutaneous mitral transcatheter edge-to-edge (TEER) was the most common (n = 12, 33.3%), followed by trancatheter aortic valve replacement (n = 11, 30.5%), and tricuspid procedures (n = 9, 25%). Mitral TEER resulted in mild residual mitral regurgitation in all but one case, mean gradient was <5 mmHg in 75% of them at 1-year, with no mortality and 8.3% re-admission rate. Tricuspid TEER resulted in 100% none/mild residual regurgitation with a 1-year mortality and readmission rates of 22% and 28.5%, respectively. Finally, trancatheter aortic valve replacement procedures (n = 8 in LVADs due to aortic regurgitation and n = 3 in HTx), were successful in all cases with one prosthesis degeneration leading to severe aortic regurgitation at 1-year, 18.2% mortality rate and no re-admissions. Globally, major bleeding rates were 7.9% and 12.5%, thromboembolic events 3.7% and 12.5%, readmissions 37% and 25%, and mortality 22% and 25%, in HTx and LVADs respectively. No death was related to the implanted transcatheter device. Conclusions: Most centers with HTx/LVAD programs perform structural percutaneous procedures but with very inconsistent incidence. They were associated with good safety and efficacy, but larger studies are required to provide formal recommendations.engCreative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC-BY-NC-ND 4.0)http://creativecommons.org/licenses/by-nc-nd/4.0/Heart transplantLVADPercutaneous therapiesTAVITEERCAVILAAOjournal articleopen access10.1016/j.ijcard.2024.132340